Turing cuts hospital price for drug it hiked 5,000%



Estimated read time: 1-2 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (CNNMoney) — The pharmaceutical company that increased the price of a drug used by AIDS and cancer patients 5,000 percent is slashing the price it will charge hospitals.

Turing Pharmaceuticals said it will offer hospitals Daraprim at up to 50 percent off the list price. It said hospitals are the first to treat 80 percent of patients who have toxoplasmosis encephalitis, the most common form of toxoplasmosis in the United States.

The company also said it would offer smaller bottles of 30 tablets to make it easier and cheaper for hospitals to carry the drug, and free sample packages for doctors needing to treat patients in emergency situations.

"We pledge that no patient needing Daraprim will ever be denied access," said Nancy Retzlaff, Turing's chief commercial officer, in a statement.

The move comes after Turing CEO Martin Shkreli said the company would lower the costs for patients after it raised its list price from $13.50 a pill to $750 a pill.

"We've agreed to lower the price of Daraprim to a price that is more affordable," Shkreli told ABC World News Tonight in September.

The initial price increase caused a public outcry. Democratic presidential candidate Hillary Clinton tweeted, "Price gouging like this in the specialty drug market is outrageous."

The Daily Beast declared Shkreli "the most-hated man in America."

Daraprim is used to treat toxoplasmosis, which the Mayo Clinic indicates is a disease caused by one of the world's most common parasites. Toxoplasmosis causes flu-like symptoms in patients.

The-CNN-Wire™ & © 2015 Cable News Network, Inc., a Time Warner Company. All rights reserved.

Related Stories

Robert McLean

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast